Medicare Part D use of GLP‑1 drugs like Ozempic and Mounjaro has surged, with Ozempic alone jumping from under 150,000 users in 2019 to 2 million in 2024.
Spending has risen sharply as well, though rebates have roughly cut net costs in half. CMS is preparing to expand access to GLP‑1s for obesity through the new BALANCE model starting in 2027, which could significantly increase demand among Medicare beneficiaries. At the same time, Medicare’s negotiated drug prices for semaglutide (2027) and dulaglutide (2028) may help control long‑term spending.
Never Miss an Update by Updating Your Contact Preferences and Following Us on Social Media!